Open AccessResearch Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists
Author(s) -
Rui Song,
Hang Qian,
Yunlian Wang,
Qingmei Li,
Dongfeng Li,
Jishun Chen,
Jingning Yang,
Jixin Zhong,
Handong Yang,
Xinwen Min,
Hao Xu,
Yong Yang,
Jun Chen
Publication year - 2022
Publication title -
journal of diabetes research
Language(s) - English
Resource type - Journals
eISSN - 2314-6753
pISSN - 2314-6745
DOI - 10.1155/2022/4554996
Subject(s) - medicine , agonist , diabetes mellitus , type 2 diabetes , glucagon like peptide 1 receptor , disease , blood sugar , receptor , endocrinology , glucagon , glucagon like peptide 1 , pharmacology , insulin
The risk of cardiovascular diseases is closely related to diabetes. Macrovascular disease is the main cause of death and disability in patients with type 2 diabetes. In recent years, the glucagon-like peptide-1 receptor agonist (GLP-1RA), a new type of hypoglycemic drug, has been shown to regulate blood sugar levels, improve myocardial ischemia, regulate lipid metabolism, improve endothelial function, and exert a protective role in the cardiovascular system. This study reviewed the protective effects of GLP-1RA on the cardiovascular system.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom